Compare Stocks: GNPX, PDSB, BLRX, and SNTI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLRX BioLineRx	$2.80 +7.7%	$2.92	$2.15 ▼ $4.56	$12.23M	1.54	29,395 shs	214,338 shs
GNPX Genprex	$3.71 +1.1%	$7.71	$3.57 ▼ $1,210.00	$3.04M	-0.88	91,217 shs	40,724 shs
PDSB PDS Biotechnology	$0.21 +1.5%	$0.62	$0.20 ▼ $1.55	$11.98M	1.62	1.01 million shs	1.35 million shs
SNTI Senti Biosciences	$0.38 +0.3%	$0.62	$0.33 ▼ $2.88	$11.78M	2.1	221,091 shs	23,976 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLRX BioLineRx	0.00%	-7.47%	-7.80%	-25.29%	-31.40%
GNPX Genprex	0.00%	-7.09%	-38.73%	-77.76%	-97.97%
PDSB PDS Biotechnology	0.00%	-3.48%	-69.26%	-81.50%	-82.99%
SNTI Senti Biosciences	0.00%	-2.99%	+10.72%	-61.54%	-74.35%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLRX BioLineRx	$2.80 +7.7%	$2.92	$2.15 ▼ $4.56	$12.23M	1.54	29,395 shs	214,338 shs
GNPX Genprex	$3.71 +1.1%	$7.71	$3.57 ▼ $1,210.00	$3.04M	-0.88	91,217 shs	40,724 shs
PDSB PDS Biotechnology	$0.21 +1.5%	$0.62	$0.20 ▼ $1.55	$11.98M	1.62	1.01 million shs	1.35 million shs
SNTI Senti Biosciences	$0.38 +0.3%	$0.62	$0.33 ▼ $2.88	$11.78M	2.1	221,091 shs	23,976 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLRX BioLineRx	0.00%	-7.47%	-7.80%	-25.29%	-31.40%
GNPX Genprex	0.00%	-7.09%	-38.73%	-77.76%	-97.97%
PDSB PDS Biotechnology	0.00%	-3.48%	-69.26%	-81.50%	-82.99%
SNTI Senti Biosciences	0.00%	-2.99%	+10.72%	-61.54%	-74.35%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLRX BioLineRx	1.00	Sell	N/A	N/A
GNPX Genprex	1.00	Sell	N/A	N/A
PDSB PDS Biotechnology	2.33	Hold	$9.00	4,105.61% Upside
SNTI Senti Biosciences	2.75	Moderate Buy	$10.00	2,636.73% Upside

Current Analyst Ratings Breakdown

Latest GNPX, PDSB, BLRX, and SNTI Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/26/2026	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	PDSB PDS Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	BLRX BioLineRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	GNPX Genprex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	PDSB PDS Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	SNTI Senti Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLRX BioLineRx	$1.40M	8.44	N/A	N/A	$5.36 per share	0.51
GNPX Genprex	N/A	N/A	N/A	N/A	$53.16 per share	N/A
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	$0.18 per share	N/A
SNTI Senti Biosciences	$55K	206.92	N/A	N/A	$0.18 per share	2.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLRX BioLineRx	-$1.17M	-$1.92	N/A	N/A	N/A	-563.70%	-37.73%	-19.42%	8/31/2026 (Estimated)
GNPX Genprex	-$16.23M	-$133.36	N/A	N/A	N/A	N/A	-163.12%	-128.98%	9/2/2026 (Estimated)
PDSB PDS Biotechnology	-$34.50M	-$0.64	N/A	N/A	N/A	N/A	-708.18%	-136.50%	11/12/2026 (Estimated)
SNTI Senti Biosciences	-$61.44M	-$1.77	N/A	N/A	N/A	N/A	-1,629.80%	-119.72%	11/12/2026 (Estimated)

Latest GNPX, PDSB, BLRX, and SNTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/31/2026	Q2 2026	BLRX BioLineRx	-$0.15	-$0.77	-$0.62	-$0.77	$0.50 million	$0.29 million
8/14/2026	Q2 2026	GNPX Genprex	N/A	-$9.40	N/A	-$9.40	N/A	N/A
8/14/2026	Q2 2026	SNTI Senti Biosciences	-$0.33	-$0.41	-$0.08	-$0.41	N/A	$0.02 million
8/13/2026	Q2 2026	PDSB PDS Biotechnology	-$0.13	-$0.18	-$0.05	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLRX BioLineRx	N/A	N/A	N/A	N/A	N/A
GNPX Genprex	N/A	N/A	N/A	N/A	N/A
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	N/A
SNTI Senti Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLRX BioLineRx	0.16	1.58	1.43
GNPX Genprex	N/A	6.76	6.76
PDSB PDS Biotechnology	2.73	0.57	0.57
SNTI Senti Biosciences	N/A	0.83	0.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLRX BioLineRx	1.56%
GNPX Genprex	14.05%
PDSB PDS Biotechnology	26.84%
SNTI Senti Biosciences	25.70%

Insider Ownership

Company	Insider Ownership
BLRX BioLineRx	1.10%
GNPX Genprex	0.25%
PDSB PDS Biotechnology	8.40%
SNTI Senti Biosciences	3.12%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLRX BioLineRx	40	4.37 million	4.32 million	Optionable
GNPX Genprex	20	820,000	818,000	No Data
PDSB PDS Biotechnology	20	55.97 million	51.27 million	Optionable
SNTI Senti Biosciences	4	31.15 million	30.17 million	Not Optionable

GNPX, PDSB, BLRX, and SNTI Headlines

Recent News About These Companies

Senti Biosciences Holdings Inc

August 11, 2026 | cnn.com

Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next ...

July 15, 2026 | markets.businessinsider.com

Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform

July 15, 2026 | globenewswire.com

Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure

May 16, 2026 | tipranks.com

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important ...

May 14, 2026 | markets.businessinsider.com $https://markets.businessinsider.com/news/stocks/senti-biosciences-holdings-announces-positive-fda-rmat-meeting-on-registrational-clinical-and-cmc-strategy-for-senti-202-in-relapsed-refractory-aml-along-with-important-efficacy-and-durability-1036155933$

Senti Biosciences Secures Up to $40 Million Financing and FDA Endorsement for SENTI-202 in Relapsed/Refractory Acute Myeloid Leukemia

May 14, 2026 | quiverquant.comQ

Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase

May 14, 2026 | globenewswire.com

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program

May 14, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/05/14/3294958/0/en/senti-biosciences-holdings-announces-positive-fda-rmat-meeting-on-registrational-clinical-and-cmc-strategy-for-senti-202-in-relapsed-refractory-aml-along-with-important-efficacy-an.html$

Senti Biosciences Holdings Inc.

May 13, 2026 | barrons.com

Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

April 13, 2026 | markets.businessinsider.com

Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

April 13, 2026 | globenewswire.com

Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies

April 1, 2026 | globenewswire.com

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

March 27, 2026 | globenewswire.com

Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference

March 23, 2026 | globenewswire.com

Senti Biosciences Amends Lease, Restructures GeneFab Sublease

March 19, 2026 | tipranks.com

Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

March 3, 2026 | tmcnet.com

Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

March 3, 2026 | globenewswire.com

Senti Biosciences to Showcase Gene Circuit Technology and Partnership Opportunities at TD Cowen Health Care Conference

February 24, 2026 | quiverquant.comQ

Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

February 24, 2026 | globenewswire.com

Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development

February 20, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX, PDSB, BLRX, and SNTI Company Descriptions

BioLineRx NASDAQ:BLRX

$2.80 +0.20 (+7.69%)

As of 04:00 PM Eastern

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Genprex NASDAQ:GNPX

$3.71 +0.04 (+1.09%)

As of 04:00 PM Eastern

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

PDS Biotechnology NASDAQ:PDSB

$0.21 +0.00 (+1.47%)

As of 04:00 PM Eastern

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

Senti Biosciences NASDAQ:SNTI

$0.38 +0.00 (+0.34%)

As of 03:59 PM Eastern

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GNPX, PDSB, BLRX, and SNTI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GNPX, PDSB, BLRX, and SNTI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GNPX, PDSB, BLRX, and SNTI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX, PDSB, BLRX, and SNTI Company Descriptions

BioLineRx NASDAQ:BLRX

Genprex NASDAQ:GNPX

PDS Biotechnology NASDAQ:PDSB

Senti Biosciences NASDAQ:SNTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GNPX, PDSB, BLRX, and SNTI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GNPX, PDSB, BLRX, and SNTI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GNPX, PDSB, BLRX, and SNTI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX, PDSB, BLRX, and SNTI Company Descriptions

BioLineRx NASDAQ:BLRX

Genprex NASDAQ:GNPX

PDS Biotechnology NASDAQ:PDSB

Senti Biosciences NASDAQ:SNTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools